Business Wire

NY-BRANDSHIELD

20.2.2020 08:02:12 CET | Business Wire | Press release

Share
BrandShield Launches ElectionShield Product to Protect Political Campaigns From Online Threats

BrandShield, a leading provider of services from brand protection to online threat hunting, has today announced the launch of ElectionShield.

Developed to protect political campaigns around the World from threats, such as fraudulent fundraising sites; phishing; social phishing; and impersonation, ElectionShield will be officially launched at one the World’s leading cybersecurity events, the RSA Conference in San Francisco, on February 24 - 28, 2020. BrandShield is exhibiting at South Expo, Booth# 3119.

ElectionShield utilizes BrandShield’s market-leading technology to protect political campaigns and candidates from a growing range of online threats. These include social impersonation; fraudulent fundraising schemes; domain squatting; sale of unauthorized merchandise; fake social media content; phishing, social phishing and fake news. The last few years have seen a proliferation of fake social media content, in some cases using ‘deep fake’ video, designed to attack politicians. According to The Guardian1 , at a US Senate intelligence committee hearing in May 2018, the Republican senator Marco Rubio warned that deep fakes would be used in “the next wave of attacks against America and western democracies”.

BrandShield can provide political candidates with the tools to monitor, detect and takedown these threats, through an AI-Based technology and online threat hunters team.

The new product brings BrandShield’s proven technology to the political sphere for the first time. Since 2013, BrandShield has provided services from brand protection to online threat hunting to a growing international blue-chip client base, including Fortune 500 and FTSE100 companies. By utilizing proprietary AI and big data-based technology, BrandShield automatically analyses content, web-metrics and many other data points, to detect and remove online threats.

The launch of ElectionShield comes as political campaigners are increasingly communicating with voters digitally, using advertising services bought from digital and social media companies like Facebook, Google, YouTube, Twitter or Instagram. This channel expansion exposes these campaigns to a growing number of online threats. The importance of engaging digitally with voters is highlighted by the increasing sums of money being spent by political campaigns. In the UK2 , according to the Electoral Commission, 42.8% of total advertising spend in the 2017 election was digital, up from 0.3% in 2011. The 2020 US Election is expected3 to see $1.6 billion spent on digital video, mostly on Facebook and Google.

Yoav Keren, CEO, BrandShield, said: “Good campaigns that communicate with voters are central to well-run elections and referendums. In terms of online campaigning, the growing range of threats, such as social impersonation, social phishing, fraudulent fundraising and fake news, weakens people’s faith. Having been a political campaigner myself, I know how important it is to ensure this faith is maintained. I am delighted that we have been able to utilize BrandShield’s proven technology in the political arena. We look forward to working with campaigns around the World.”

1 https://www.theguardian.com/technology/ng-interactive/2019/jun/22/the-rise-of-the-deepfake-and-the-threat-to-democracy

2 https://www.electoralcommission.org.uk/who-we-are-and-what-we-do/changing-electoral-law/transparent-digital-campaigning/report-digital-campaigning-increasing-transparency-voters

3 https://www.politico.com/f/?id=0000016b-b029-d027-a97f-f6a95aca0000

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye